<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto de Ensino e Pesquisa Albert Einstein</publisher-name>
        <publisher-loc>Sao Paulo</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26154556</article-id>
      <article-id pub-id-type="pmc">4943835</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082015MD3106</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082015MD3106</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Medical Developments</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fecal microbiota transplant by push enteroscopy to treat diarrhea caused by <italic>Clostridium difficile</italic>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ganc</surname>
            <given-names>Arnaldo Jos&#xE9;</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ganc</surname>
            <given-names>Ricardo Leite</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reim&#xE3;o</surname>
            <given-names>S&#xED;lvia Mansur</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Frisoli</surname>
            <given-names>Alberto</given-names>
            <suffix>Junior</suffix>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pasternak</surname>
            <given-names>Jacyr</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Universidade Federal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil</aff>
        <aff id="aff2"><label>2</label>Hospital Israelita Albert Einstein, S&#xE3;o Paulo, SP, Brazil</aff>
        <aff id="aff3"><label>3</label>Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">Corresponding author: Silvia Mansur Reim&#xE3;o - Avenida Albert Einstein, 627/701 - Morumbi - Zip code: 05652-900 - S&#xE3;o Paulo, SP, Brazil - Phone: <phone>(55 11) 95282-0002</phone> - E-mail: <email>silvia_mansur@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Apr-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Apr-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>13</volume>
      <issue>2</issue>
      <fpage>338</fpage>
      <lpage>339</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>2</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <p>
<italic>Clostridium difficile</italic> is the major etiological agent of pseudomembranous colitis and is found in up to 20% of adult inpatients. The recommended treatment is antibiotic therapy with metronidazole and/or vancomycin. However, the recurrence rate may reach up to 25% and it increases in each episode. The newest alternative to treat diarrhea due to recurrent <italic>Clostridium difficile</italic> is fecal microbiota transplantation. The procedure was performed in 12 patients, with a 6-month follow-up on 10 of them. Of the ten cases, bacterial recurrence was diagnosed in only one patient, after a course of antibiotic to treat urinary tract infection, without presenting with diarrhea. The particularity of our study, besides being an unprecedented event in South America, is the way to perform the infusion of fecal microbiota by enteroscopy.</p>
      </abstract>
      <kwd-group>
        <title>Keywords:</title>
        <kwd>
          <italic>Clostridium difficile</italic>
        </kwd>
        <kwd>Transplantation homologous</kwd>
        <kwd>Enterocolitis, pseudomembranous/etiology</kwd>
        <kwd>Endoscopy/methods</kwd>
        <kwd>Diarrhea/drug therapy</kwd>
        <kwd>Metronidazole/therapeutic use</kwd>
        <kwd>Vancomycin/therapeutic use</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="4"/>
        <page-count count="2"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>
<italic>Clostridium difficile</italic>, the main etiological agent of pseudomembranous colitis, is an anaerobic, sporeforming, Gram-positive bacillus present in the intestinal flora of up to 20% of hospitalized adults. Of these patients, only 1 to 5% develop diarrhea and the rest remains asymptomatic. The risk of contracting the infection seems to be directly proportional to the length of stay, and is related to the use of antibiotics. However, the incidence, intensity and recurrence rate of this disease have been increasing. Furthermore, the introduction of the polymerase chain reaction (PCR) technique to screen for <italic>Clostridium difficile</italic> made the detection of this organism significantly more effective, which may explain the striking increase in incidence of this infection.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
    <p>The clinical picture resulting from this infection ranges from asymptomatic cases, to diarrhea that improves by simply discontinuing antibiotics and applying clinical support measures, or event to cases of uncontrollable diarrhea, with subsequent sepsis and toxic megacolon. The mortality rate can be as high as 58% in the latter cases.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
    <p>The treatment currently recommended is antibiotic therapy with metronidazole and/or vancomycin.</p>
    <p>The response to antibiotics may be poor, and the recurrence rate can reach up to 25%. After the first relapse, the risk of a second one rises to 40%, and for multiple recurrences, the risk exceeds 50%.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> Recently, fidaxomicin emerged as an alternative for cases of resistant <italic>Clostridium difficile</italic>. Though more efficient than traditional antibiotics, this drug is not yet available in Brazil, and its efficacy has not been definitively assessed.</p>
    <p>The most recent alternative for the treatment of diarrhea caused by recurrent <italic>Clostridium difficile</italic> is fecal microbiota transplantation.</p>
    <p>The concept is not new and the first publications date back to 1958.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup> However, for many reasons, either cultural or due to disbelief among the scientific community, it took more than five decades for this line of thought to be resumed. In the beginning of the decade, several articles described the use of fecal microbiota transplantation in patients with recurrent <italic>Clostridium difficile</italic> infection. However, the medical community remained incredulous. It was only last year -after a publication in The New England Journal of Medicine (NEJM) - that the medical community realized how promising this technique could be. The most impressive about the article published in the NEJM was the striking difference between the groups treated with antibiotics or fecal microbiota transplantation. The latter was so superior that the study was interrupted by the Institutional Review Board of the organization.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
    <p>In previous publications, the infusion of fecal microbiota was performed using enemas, colonoscopies or slow infusion by nasogastric tube, with the patient awake.<sup>(<xref rid="B1" ref-type="bibr">1</xref>&#x2013;<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
    <p>The donor is usually a family member of the patient who meets certain criteria, such as not having used antibiotics in the previous six months, being immunocompromised, and having no history of illicit drug use, tumors or inflammatory bowel disease. Some tests are performed for screening: serology for hepatitis A, B and C, human immunodeficiency virus (HIV), fecal parasitology, fecal test for <italic>Clostridium difficile</italic>, and fecal culture. After donor selection, the fecal material is collected and processed in the laboratory by dilution with 0.9% saline, resulting in the solution to be infused into the recipient.</p>
    <p>We recently had the opportunity to discuss an unprecedented case of an 82-year-old patient with chronic renal failure and <italic>Clostridium difficile</italic> diarrhea for over 4 months. The patient was treated with metronidazole and vancomycin several times with numerous relapses. He was offered the option to receive a fecal microbiota transplantation. His only condition was that he did not witness the nasoenteral infusion. For this reason, we chose to perform the fecal microbiota transplantation endoscopically, under sedation, infusing the microbiota through the working channel in the proximal jejunum. The procedure was uneventful and, to our surprise, the diarrhea stopped within 24 hours.</p>
    <p>Patient has been followed-up for about 12 months with no clinical relapse.</p>
    <p>Since then, we have carried out another 12 cases, 10 of which over 6 months ago. In only one of these 10 cases did the bacterial infection relapse, after a new cycle of antibiotic therapy to treat an urinary tract infection, without diarrhea. In addition to its being an unprecedented case in South America, another particularity of our case series was the method for the fecal microbiota infusion.</p>
    <p>To date, there are no reports in the literature of fecal microbiota transplantations performed by oral push enteroscopy. We believe this is a good alternative for not requiring the patient to be subjected to colonoscopy, or exposed to the physical and moral discomfort of receiving a nasoenteral infusion of fecal material.</p>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kassam</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis</article-title>
          <source>Am J Gastroenterol</source>
          <year>2013</year>
          <volume>108</volume>
          <issue>4</issue>
          <fpage>500</fpage>
          <lpage>508</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">23511459</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rubin</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Gessert</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Aas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bakken</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series</article-title>
          <source>Anaerobe</source>
          <year>2013</year>
          <volume>19</volume>
          <fpage>22</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="pmid">23182843</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>CP</given-names>
            </name>
          </person-group>
          <article-title>Fecal microbiota transplantation&#x2013;an old therapy comes of age</article-title>
          <source>N Eng J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <issue>5</issue>
          <fpage>474</fpage>
          <lpage>475</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eiseman</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Silen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bascom</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Kauvar</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis</article-title>
          <source>Surgery</source>
          <year>1958</year>
          <volume>44</volume>
          <issue>5</issue>
          <fpage>854</fpage>
          <lpage>859</lpage>
          <pub-id pub-id-type="pmid">13592638</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S1" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Avan&#xE7;os M&#xE9;dicos</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Transplante de microbiota fecal por enteroscopia alta para o tratamento da diarreia causada por <italic>Clostridium difficile</italic>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ganc</surname>
            <given-names>Arnaldo Jos&#xE9;</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ganc</surname>
            <given-names>Ricardo Leite</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reim&#xE3;o</surname>
            <given-names>S&#xED;lvia Mansur</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
<sup>3</sup>
</xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Frisoli</surname>
            <given-names>Alberto</given-names>
            <suffix>Junior</suffix>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pasternak</surname>
            <given-names>Jacyr</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <aff id="aff4"><label>1</label>Universidade Federal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasi</aff>
        <aff id="aff5"><label>2</label>Hospital Israelita Albert Einstein, S&#xE3;o Paulo, SP, Brasil</aff>
        <aff id="aff6"><label>3</label>Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasi</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2">Autor correspondente: Silvia Mansur Reim&#xE3;o - Avenida Albert Einstein, 627/701 - Morumbi - CEP: 05652-900 - S&#xE3;o Paulo, SP, Brasil - Tel.: <phone>(11) 95282-0002</phone> - E-mail: <email>silvia_mansur@yahoo.com.br</email></corresp>
      </author-notes>
      <abstract>
        <title>RESUMO</title>
        <p>O <italic>Clostridium difficile</italic> &#xE9; o principal agente etiol&#xF3;gico da colite pseudomembranosa e est&#xE1; presente em at&#xE9; 20% dos adultos hospitalizados. O tratamento recomendado &#xE9; a antibioticoterapia com metronidazol e/ou vancomicina. No entanto, a taxa de recidiva chega a 25% e aumenta conforme a recorr&#xEA;ncia. A mais recente alternativa para o tratamento da diarreia por <italic>Clostridium difficile</italic> recorrente &#xE9; o transplante de microbiota fecal. Realizamos 12 casos, tendo 10 deles ocorridos h&#xE1; mais de 6 meses. Desses dez casos, houve recidiva bacteriana em apenas um deles, ap&#xF3;s novo ciclo de antibi&#xF3;tico para tratamento de infec&#xE7;&#xE3;o do trato urin&#xE1;rio, sem a presen&#xE7;a de diarreia. A particularidade da nossa casu&#xED;stica, al&#xE9;m de ser um fato in&#xE9;dito na Am&#xE9;rica do Sul, deveu-se &#xE0; maneira de realizar a infus&#xE3;o da microbiota fecal, que foi por via enterosc&#xF3;pica.</p>
      </abstract>
      <kwd-group>
        <title>Descritores:</title>
        <kwd>
          <italic>Clostridium difficile</italic>
        </kwd>
        <kwd>Transplante hom&#xF3;logo</kwd>
        <kwd>Enterocolite pseudomembranosa/etiologia</kwd>
        <kwd>Endoscopia/m&#xE9;todos</kwd>
        <kwd>Diarreia/quimioterapia</kwd>
        <kwd>Metronidazol/uso terap&#xEA;utico</kwd>
        <kwd>Vancomicina/uso terap&#xEA;utico</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>O <italic>Clostridium difficile</italic>, principal agente etiol&#xF3;gico da colite pseudomembranosa, &#xE9; um bacilo <italic>Gram</italic>-positivo, anaer&#xF3;bio e esporulado presente na flora intestinal de at&#xE9; 20% dos adultos hospitalizados. Destes, somente 1 a 5% desenvolvem diarreia, e o restante permanece assintom&#xE1;tico. O risco de contrair a infec&#xE7;&#xE3;o parece ser diretamente proporcional ao tempo de interna&#xE7;&#xE3;o e est&#xE1; relacionado ao uso de antibi&#xF3;ticos. No entanto, incid&#xEA;ncia, intensidade e taxa de recorr&#xEA;ncia dessa afec&#xE7;&#xE3;o v&#xEA;m aumentando. Al&#xE9;m disso, a introdu&#xE7;&#xE3;o da t&#xE9;cnica de rea&#xE7;&#xE3;o em cadeia da polimerase (PCR) para a pesquisa de <italic>Clostridium difficile</italic> aumentou significativamente a efic&#xE1;cia da detec&#xE7;&#xE3;o da bact&#xE9;ria, o que talvez explique o incr&#xED;vel aumento da incid&#xEA;ncia dessa infec&#xE7;&#xE3;o.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
      <p>O quadro cl&#xED;nico decorrente dessa infec&#xE7;&#xE3;o varia desde quadros assintom&#xE1;ticos, diarreia que melhora com a simples a descontinua&#xE7;&#xE3;o do antibi&#xF3;tico e medidas de suporte cl&#xED;nico, at&#xE9; quadros de diarreia incoerc&#xED;vel, com consequente sepse e megac&#xF3;lon t&#xF3;xico. A taxa mortalidade pode chegar a 58% nesses quadros.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
      <p>Atualmente, o tratamento recomendado &#xE9; a antibioticoterapia com metronidazol e/ou vancomicina.</p>
      <p>A resposta &#xE0; antibioticoterapia pode ser prec&#xE1;ria, e a taxa de recorr&#xEA;ncia chega a 25%. Ap&#xF3;s a primeira recorr&#xEA;ncia, o risco de apresentar uma segunda recorr&#xEA;ncia aumenta para 40% e, para m&#xFA;ltiplas recorr&#xEA;ncias, o risco ultrapassa 50%.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> Recentemente, a fidaxomicina surgiu como uma alternativa para os casos de <italic>Clostridium difficile</italic> resistentes. Apesar de mais eficiente que os antibi&#xF3;ticos tradicionais, essa medica&#xE7;&#xE3;o ainda n&#xE3;o est&#xE1; dispon&#xED;vel no nosso meio, e sua efic&#xE1;cia n&#xE3;o est&#xE1; definitivamente avaliada.</p>
      <p>A mais recente alternativa para o tratamento da diarreia por <italic>Clostridium difficile</italic> recorrente &#xE9; o transplante de microbiota fecal.</p>
      <p>O conceito n&#xE3;o &#xE9; novo e as primeiras publica&#xE7;&#xF5;es a respeito datam de 1958.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup> Por&#xE9;m, por v&#xE1;rios motivos, desde culturais at&#xE9; a descren&#xE7;a do meio cient&#xED;fico, passaram-se mais de cinco d&#xE9;cadas at&#xE9; que essa linha de racioc&#xED;nio fosse retomada. No in&#xED;cio dessa d&#xE9;cada, foram publicados v&#xE1;rios artigos segundo os quais utilizou-se o transplante de microbiota fecal para pacientes com recorr&#xEA;ncia da infec&#xE7;&#xE3;o por <italic>Clostridium difficile</italic>. Mesmo assim, o meio m&#xE9;dico manteve-se incr&#xE9;dulo. Foi somente no ano passado, com uma publica&#xE7;&#xE3;o no <italic>The New England Journal of Medicine</italic> (NEJM), que a comunidade m&#xE9;dica percebeu o qu&#xE3;o promissora pode ser essa t&#xE9;cnica. O mais impressionante do trabalho publicado no NEJM foi a discrep&#xE2;ncia dos resultados apresentados entre o grupo tratado com antibi&#xF3;ticos e o tratado com transplante de microbiota fecal. Este &#xFA;ltimo foi t&#xE3;o superior que o estudo foi interrompido pelo Comit&#xEA; de &#xC9;tica M&#xE9;dica da institui&#xE7;&#xE3;o.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
      <p>Nas publica&#xE7;&#xF5;es anteriores, a infus&#xE3;o da microbiota fecal foi realizada por meio de enemas, colonoscopias ou infus&#xF5;es lentas por sonda nasoenteral, com o paciente acordado.<sup>(<xref rid="B1" ref-type="bibr">1</xref>&#x2013;<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
      <p>O indiv&#xED;duo doador &#xE9; geralmente um membro da fam&#xED;lia do paciente e que se enquadra em alguns crit&#xE9;rios, como n&#xE3;o ter feito uso de antibi&#xF3;tico nos &#xFA;ltimos 6 meses, ser imunocomprometido, e n&#xE3;o ter antecedente de uso de drogas il&#xED;citas, tumor ou doen&#xE7;a inflamat&#xF3;ria intestinal. S&#xE3;o feitos alguns exames para triagem: sorologia para hepatites A, B e C, v&#xED;rus da imunodefici&#xEA;ncia humana (HIV), protoparasitol&#xF3;gico de fezes, pesquisa de <italic>Clostridium difficile</italic> nas fezes, al&#xE9;m de cultura fecal. Uma vez selecionado o doador, o material fecal &#xE9; colhido e processado em laborat&#xF3;rio, de modo que fique dilu&#xED;do com soro fisiol&#xF3;gico a 0,9%, formando a solu&#xE7;&#xE3;o a ser infundida no indiv&#xED;duo receptor.</p>
      <p>Recentemente, tivemos a oportunidade de tratar, de forma in&#xE9;dita no nosso meio, um caso de um paciente de 82 anos com insufici&#xEA;ncia renal cr&#xF4;nica e diarreia por <italic>Clostridium difficile</italic> h&#xE1; mais de 4 meses. O paciente foi tratado com metronidazol e vancomicina por v&#xE1;rias vezes, sempre com recidiva do quadro. A ele foi oferecida a op&#xE7;&#xE3;o do tratamento com transplante de microbiota fecal. A &#xFA;nica condi&#xE7;&#xE3;o imposta por ele foi de que n&#xE3;o presenciasse a infus&#xE3;o por via nasoent&#xE9;rica. Por esse motivo, optamos pela realiza&#xE7;&#xE3;o do transplante de microbiota fecal por via endosc&#xF3;pica, sob seda&#xE7;&#xE3;o, com a microbiota sendo infundida por meio do canal de trabalho no jejuno proximal. O procedimento transcorreu sem intercorr&#xEA;ncias e, para a nossa surpresa, a diarreia cessou em 24 horas.</p>
      <p>O paciente permanece em acompanhamento h&#xE1; cerca de 12 meses, sem recidiva cl&#xED;nica do quadro.</p>
      <p>Desde ent&#xE3;o, j&#xE1; realizamos 12 casos, sendo 10 deles h&#xE1; mais de 6 meses. Destes dez casos, houve recidiva bacteriana em um deles, ap&#xF3;s novo ciclo de antibi&#xF3;tico para tratamento de infec&#xE7;&#xE3;o do trato urin&#xE1;rio, sem a presen&#xE7;a de diarreia. A particularidade da nossa casu&#xED;stica, al&#xE9;m de ser um fato in&#xE9;dito na Am&#xE9;rica do Sul, deveu-se &#xE0; maneira de realizar a infus&#xE3;o da microbiota fecal.</p>
      <p>At&#xE9; o presente momento, n&#xE3;o h&#xE1; relatos na literatura de transplante de microbiota fecal por meio de enteroscopia, por via oral. Acreditamos que essa seja uma boa alternativa para tal, uma vez que o paciente n&#xE3;o precisa se submeter a uma colonoscopia para a infus&#xE3;o do material, nem ficar exposto ao desconforto f&#xED;sico e moral da infus&#xE3;o por via nasoenteral do material fecal.</p>
    </body>
  </sub-article>
</article>
</pmc-articleset>
